Ai Mediq S.A.

Ai Mediq S.A. was established to commercialize the knowledge of positive effects of short-term acute hypoxia on the human body. Hypoxia signaling pathway management is a new generation of intervention, leveraging the potential of hypoxia-inducible factors (HIFs) as a master regulator of oxygen homeostasis in all tissues, which controls oxygen delivery, by regulating angiogenesis and vascular remodeling, and oxygen utilization, by regulating glucose metabolism and redox homeostasis. As a master regulator of multiple downstream targets, HIF exerts diverse functions and should be altered with caution.

Ai Mediq is the first in the world to develop

• Way to dose hypoxic load based on the response of the human body to the hypoxic gas mixture inhaling
• Algorithm for calculation of individual therapeutic hypoxic dose
• New modality, that allows reducing the hypoxic load intensity without compromising the treatment efficacy – the Intermittent Hypoxia Hyperoxia Training (IHHT) mode
• New device to deliver the IHHT method involving the bio feed-back with automatic calculation of individual treatment hypoxia dose.

We believe hypoxia-management treatment by the HIF activation could represent an innovative approach to treating certain conditions where there is an unmet need. The clinical trials have demonstrated the evidence of efficacy dosed hypoxia in the rehabilitation of cardiac patients, dementia elderly people, rehabilitation after spinal trauma and stroke.